Basis: FMP quote price / unrounded FMP forward EPS in the trading currency, available after its recorded retrieval time. Source: stored company filings and market data; unavailable inputs remain N/A.
The forward PE ratio is 86.03 as of 2026-10-06T12:01:11.882Z.
Consensus retrieved: 2026-10-06T09:14:48.152Z. This records retrieval, including cache reads, rather than vendor publication. The calculation uses the separately dated price and estimate available at its as-of time.
Calculation as of: 2026-10-06T12:01:11.882Z.
Quote observation: 2026-10-05T20:00:01.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: a72309f06b08c72c2b13679a6c04d7377123f27200b220b385dcfb2827f471f2
Forward PE Ratio (86.03) = Dated Quote Price ($42.73) / Consensus Forward EPS ($0.50)
FORWARD PE RATIO
86.03
SECTOR MEDIAN · HEALTHCARE
19.84
median of 122 covered companies
CURRENT VS SECTOR MEDIAN
+333.73%
vs the sector median at left
Azenta, Inc.
Market Cap
$1.97B
Forward PE Ratio
86.03
| NAME | MARKET CAP | FORWARD PE RATIO |
|---|---|---|
| Azenta, Inc. (AZTA) | $1.97B | 86.03 |
| Establishment Labs Holdings Inc. (ESTA)vs › | $1.96B | N/A |
| Absci Corporation (ABSI)vs › | $1.95B | N/A |
| AxoGen, Inc. (AXGN)vs › | $2.00B | 84.11 |
| Fortrea Holdings Inc. (FTRE)vs › | $2.01B | 25.10 |
| Aurinia Pharmaceuticals Inc. (AUPH)vs › | $2.02B | 16.65 |
| Inspire Medical Systems, Inc. (INSP)vs › | $2.05B | 59.24 |
| BioLife Solutions, Inc. (BLFS)vs › | $1.89B | 64.35 |
| BioCryst Pharmaceuticals, Inc. (BCRX)vs › | $2.06B | N/A |
| Alvotech (ALVO)vs › | $2.07B | N/A |
Trailing P/E
N/A
reported TTM EPS
Forward P/E
86.0
consensus EPS · fiscal year ending 2027-09-30
At the dated quote price of $42.73, each upcoming fiscal year's consensus EPS implies a different multiple — how quickly the price is "paid down" by expected earnings if the estimates hold.
| Fiscal year end | Consensus EPS | Estimate range | Analysts | Implied P/E |
|---|---|---|---|---|
| 2027-09-30 | $0.50 | $0.49 – $0.50 | 2 | 86.0x |
| 2028-09-30 | $0.79 | $0.78 – $0.79 | 1 | 54.4x |
| 2029-09-30 | $1.30 | $1.29 – $1.31 | 1 | 32.9x |
Source: FMP analyst consensus estimates, refreshed with the daily precompute. "n/m" = the consensus EPS is not positive, so a multiple is undefined. There is no forward P/E history chart here because charting one would require the estimates as they stood in the past, which we do not store — see the trailing P/E history for how the realized multiple has moved.
PE Ratio = Share Price / Diluted EPS (TTM)
The price-to-earnings ratio measures how much investors pay for each dollar of trailing earnings. A lower PE can indicate a cheaper valuation; a higher PE implies higher growth expectations.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
